The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2
Public ClinicalTrials.gov record NCT04313023. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Subjects who have documented exposure to SARS-CoV-2 (COVID-19) will receive 4 doses of PUL-042 Inhalation Solution or 4 doses of a placebo solution by inhalation over 10 days. Subjects will be followed for the incidence and severity of COVID-19 over 28 days. Subjects will be tested for infection with SARS-CoV-2 at the beginning, middle and end of the study.
Study identification
- NCT ID
- NCT04313023
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 217 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 9, 2020 (Actual)
- Primary completion
- Jul 31, 2021 (Actual)
- Completion
- Jul 31, 2021 (Actual)
- Last update posted
- May 17, 2023
2020 – 2021
United States locations
- U.S. sites
- 15
- U.S. states
- 6
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California Irvine | Orange | California | 92868 | — |
| Premier Urgent Care of California | San Bernardino | California | 92404 | — |
| Clinical Research of South Florida Alliance for Multispecialty Research | Coral Gables | Florida | 33134 | — |
| Invesclinic US LLC | Fort Lauderdale | Florida | 33308 | — |
| Luminous Cinical Research- South Florida Urgent Care | Miami | Florida | 33136 | — |
| Entrust Clinical Research | Miami | Florida | 33156 | — |
| DBC Research | Tamarac | Florida | 33321 | — |
| Affinity Clinical Research, LLC | Tampa | Florida | 33612 | — |
| Clinical Research Atlanta | Stockbridge | Georgia | 30281 | — |
| Willis-Knighton Physcian Network | Bossier City | Louisiana | 71111 | — |
| Ascension St John | Bartlesville | Oklahoma | 74006 | — |
| Ascension St. John | Tulsa | Oklahoma | 74104 | — |
| Invesclinic US LLC | Edinburg | Texas | 78539 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Next Level Urgent Care | Houston | Texas | 77057 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04313023, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 17, 2023 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04313023 live on ClinicalTrials.gov.